|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||666.00 - 680.00|
|52-week range||666.00 - 680.00|
|Beta (5Y monthly)||0.33|
|PE ratio (TTM)||174.66|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Bio-Rad's equity position in a German pharma company is an asset many investors may not realize.
SARTORIUS AG (SARTF) is well positioned to outperform the market, as it exhibits above-average growth in financials.
SARTORIUS AG (SARTF) possesses solid growth attributes, which could help it handily outperform the market.